Psychopharmacology

, Volume 108, Issue 3, pp 248–255 | Cite as

Rebound insomnia and newer hypnotics

  • Malcolm Lader
Review

Abstract

The prescription of hypnotics, mostly benzodiazepines, continues at a high level. One problem with their use is rebound insomnia: upon discontinuation sleep worsens compared with pretreatment levels. Factors influencing rebound include the type of subject, the duration of action of the hypnotic, the dosage and perhaps duration of treatment. The detection of rebound requires both sleep-laboratory and clinical studies with night-by-night analyses of individual patient data. This review concentrates on the newer compounds, (quazepam and zolpidem) which act selectively on subtypes of benzodiazepine receptors or bind atypically (zopiclone). It concludes that present evidence, while limited, is consistent with claims of less rebound potential than older benzodiazepine hypnotics of equivalent duration of action. Nevertheless, further rigorous studies are essential before these claims can be totally accepted.

Key words

Rebound insomnia Benzodiazepines Quazepam Zopiclone Zolpidem 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adam K, Adamson L, Brezinova V, Hunter WM, Oswald I (1976) Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 1:1558–1560Google Scholar
  2. Adam K, Oswald I, Shapiro C (1984) Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology 82:389–394Google Scholar
  3. Allen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E (1987) Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol 27:768–775Google Scholar
  4. Anderson AA (1987) Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 10 [suppl 1]:54–62Google Scholar
  5. Ankier SI, Goa KL (1988) Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35:42–62Google Scholar
  6. Besset A, Tafti M, Barthouil P, Rossi P, Billiard M (1990) Effect of zolpidem 10 mg on sleep architecture and daytime psychomotor skills in poor sleepers. 4th Annual Meeting of the Association of Professional Sleep Societies, MinneapolisGoogle Scholar
  7. Bixler EO, Kales A, Soldatos CR, Kales JD (1977) Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations. J Clin Pharmacol 17:569–578Google Scholar
  8. Clark BG, Jue SG, Dawson GW, Ward A (1986) Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 31:500–516Google Scholar
  9. Costa E, Puia G, Vicini S (1991) Impact of current developments in molecular biology on the pharmacotherapy of anxiety disorders. In: Meltzer D, Nerozzi D (eds) Current practices and future developments in the pharmacotherapy of mental disorders. ElsevierGoogle Scholar
  10. Curran HV, Schifano F, Lader M (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103:83–90Google Scholar
  11. Dorian P, Sellers EM, Kaplan H, Hamilton C (1982) Evaluation of zopiclone physical dependence liability in normal volunteers. Int Pharmacopsychiatr 17 [suppl 2]:228–234Google Scholar
  12. Dunbar GC et al. (1989) Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 155:836–841Google Scholar
  13. Elie R, Prenay M, Le Morvan P, Bourgouin J (1990a) Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 5 [suppl 2]:39–46Google Scholar
  14. Elie R, Lavoie G, Bourgouin J, Le Morvan P (1990b) Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 5:279–286Google Scholar
  15. Emeriau JP, Descamps A, Dechelotte P, Poch B, Harribey B, Alla P, Colle M (1988) Zolpidem and flunitrazepam: a multicenter trial in elderly hospitalized patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 317–326Google Scholar
  16. Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J (1990) A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 5 [suppl 2]:29–38Google Scholar
  17. Gaillot J, Le Roux Y, Houghton GW, Dreyfus JP (1987) Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 10 [suppl 1]:7–21Google Scholar
  18. Goa KL, Heel RC (1986) Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 32:48–65Google Scholar
  19. Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: A critical review. J Clin Psychopharmacol 9:161–172Google Scholar
  20. Godtlibsen OB, Dreyfus JF (1980) Effect of 7.5 mg zopiclone (27.267RP) on sleep pattern in normal subjects. Waking and Sleeping 4:319–325Google Scholar
  21. Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. New Engl J Med 317:722–728Google Scholar
  22. Greenblatt DJ, Miller LG, Shader RI (1990) Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 88 [suppl 3A]:18S-24SGoogle Scholar
  23. Guelfi JD (1990) Nouveaux psychotropes et cycles du sommeil. Ann Psychiatr 4:314–317Google Scholar
  24. Herrmann WM, Kubicki St, Wober W (1988) Zolpidem: a four-week pilot polysomnographic study in patients with chronic sleep disturbances. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 261–278Google Scholar
  25. Jovanovic UJ, Dreyfus JF (1982) Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Int Pharmacopsychiatr 17 [suppl 2]:136–145Google Scholar
  26. Julou L, Blanchard JC, Dreyfus JP (1985) Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 23:653–659Google Scholar
  27. Kales A (1990) Quazepam: hypnotic efficacy and side effects. Pharmacotherapy 10:1–12Google Scholar
  28. Kales A, Kales JD (1984) Evaluation and treatment of insomnia. Oxford University Press, OxfordGoogle Scholar
  29. Kales A, Bixler EO, Scharf M, Kales JD (1976) Sleep laboratory studies of flurazepam: a model for evaluating hypnotic drugs. Clin Pharmacol Ther 19:576–583Google Scholar
  30. Kales A, Scharf MB, Kales JD (1978) Rebound insomnia: a new clinical syndrome. Science 201:1039–1040Google Scholar
  31. Kales A, Scharf MB, Kales JD, Soldatos CR (1979) Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA 241:1692–1695Google Scholar
  32. Kales A, Bixler EO, Soldatos CR (1982a) Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia. J Clin Pharmacol 22:520–530Google Scholar
  33. Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1982b) Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther 32:781–788Google Scholar
  34. Kales A, Soldatos CR, Bixler E, Goff PJ, Vela-Bueno A (1983a) Midazolam: dose-response studies of effectiveness and rebound insomnia. Pharmacology 26:138–149Google Scholar
  35. Kales A, Soldatos CR, Bixler EO, Kales JD (1983b) Rebound insomnia and rebound anxiety: a review. Pharmacology 24:121–137Google Scholar
  36. Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD (1986a) Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 32:121–130Google Scholar
  37. Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1986b) Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther 39:345–352Google Scholar
  38. Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Niklaus DE, Manfredi RL (1986c) Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther 40:378–386Google Scholar
  39. Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL (1987) Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 27:508–515Google Scholar
  40. Kales JD, Kales A, Soldatos CR (1985) Quazepam: sleep laboratory studies of effectiveness and withdrawal. Neuropharmacology 8:S55–62Google Scholar
  41. Kurtz D, Baas V, Rumbach L (1990) Effects on nocturnal sleep and daytime vigilance of zolpidem 10 mg administered during 14 nights to poor sleepers. Abstract of 1st Conference — Congress of European Sleep Research Society StrasbourgGoogle Scholar
  42. Lader M, Frcka G (1987) Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 20:67–71Google Scholar
  43. Lader M, Lawson C (1987) Sleep studies and rebound insomnia: methodological problems, laboratory findings, and clinical implications. Clin Neuropharmacology 10:291–312Google Scholar
  44. Lamphere J, Roehrs T, Vogel G, Koshorek G, Fortier J, Roth T (1990) The chronic efficacy of midazolam. Int Clin Psychopharmacol 5:31–39Google Scholar
  45. Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A (1988) Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 55–70Google Scholar
  46. Langley MS, Clissold SP (1988) Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 35:104–122Google Scholar
  47. Langtry HD, Benfield P (1990) Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291–313Google Scholar
  48. Lorizio A, Terzano MG, Parrino L, Cesana BM, Priorie P (1990) Zolpidem: a double-blind comparison of the hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 47:889–898Google Scholar
  49. Maggioni M, Frattola L (1988) Double-blind controlled study of the efficacy and safety of zolpidem versus flunitrazepam. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 386–387Google Scholar
  50. Mamelak M, Csima A, Price V (1982) Effects of zopiclone on the sleep of chronic insomniacs. Int Pharmacopsychiatr 17 [suppl 2]:156–164Google Scholar
  51. Mamelak M, Csima A, Buck L, Price V (1989) A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 9:260–267Google Scholar
  52. Mamelak M, Csima A, Price V (1990) The effects of a single night's dosing with triazolam on sleep the following night. J Clin Pharmacol 30:549–555Google Scholar
  53. McClure DJ, Walsh J, Chang H, Olah A, Wilson R, Pecknold JC (1988) Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. J Clin Pharmacol 28:52–63Google Scholar
  54. Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gerne M, Strauch I, Lehmann D, Borbély AA (1982) Day-time residual effects and motor activity after three benzodiazepine hypnotics. Drug Res 32[I]:461–465Google Scholar
  55. Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Arch Gen Psychiatry 42:225–232Google Scholar
  56. Mello de Paula AJ (1983) Comparative study of zopiclone and pentobarbitone as hypnotics. Pharmacology 27 [suppl 2]:188–195Google Scholar
  57. Mereu G, Carcangiu G, Concas A, Passino N, Biggio G (1990) Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors. Eur J Pharmacol 179:339–346Google Scholar
  58. Merlotti L, Roehrs T, Zorick FJ, Roth T (1991) Rebound insomnia: Duration of use and individual differences. J Clin Psychopharmacol 11:368–373Google Scholar
  59. Monti JM (1989) Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461–466Google Scholar
  60. Morgan K (1990) Hypnotics in the elderly. What cause for concern? Drugs 10:688–696Google Scholar
  61. Morgan K, Tomeny M (1988) Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 78:297–298Google Scholar
  62. Morgan K, Dallsoo H, Ebrahim S, Arie T, Fentem PH (1988) Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. BMJ 296:601–602Google Scholar
  63. Mouret J, Ruel D, Maillard P, Bianchi M (1990) Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 5:47–55Google Scholar
  64. Oswald I, Adam K, Borrow S, Idzikowski C (1979) The effects of two hypnotics on sleep, subjective feelings and skilled performance. In: Pussouant O, Oswald I (eds) Pharmacology of the states of alertness. Pergamon Press, Oxford, pp 51–63Google Scholar
  65. Oswald I, French C, Adam K, Gilham J (1982) Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 284:860–863Google Scholar
  66. Pecknold J, Wilson R, Le Morvan P (1990) Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5 [suppl 2]:57–67Google Scholar
  67. Prinz PN, Vitiello MV, Raskin MA, Thorpy MJ (1990) Geriatrics: sleep disorders and aging. New Engl J Med:520–526Google Scholar
  68. Quadens OP, Hoffman G, Buytaert G (1982) Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. Int Pharmacopsychiatr 17 [suppl 2]:146–155Google Scholar
  69. Roehrs T, Zorick F, Wittig R, Roth T (1986) Dose determinants of rebound insomnia. Br J Clin Pharmacol 22:143–147Google Scholar
  70. Roehrs T, Vogel G, Roth R (1990) Rebound insomnia: its determinants and significance. Am J Med 88 [suppl 3A]:395–425Google Scholar
  71. Roth T, Kramer M, Roehrs T (1977) The consistency of sleep measures. In: Proceedings of the 3rd European Congress on Sleep Research, Montpellier. Karger, Basel, pp 286–288Google Scholar
  72. Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B (1988) Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 339–349Google Scholar
  73. Scharf MB, Sachais BA, Mayleben DW, Fletcher K, Jennings SW (1990) A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0.125 and 0.25 mg in chronic insomnia. Curr Ther Res 18:555–567Google Scholar
  74. Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R (1991) Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 52:2:77–83Google Scholar
  75. Schlich D, L'Heritier C, Coquelin JP, Attali P (1991) Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271–279Google Scholar
  76. Schneider-Helmert D (1988) Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 78:706–711Google Scholar
  77. Shaw SH (1988) Double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, p 389Google Scholar
  78. Spinweber CL, Johnson LC (1982) Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology 76:5–12Google Scholar
  79. Tham TCK, Brown H, Taggart HMcA (1989) Temazepam withdrawal in elderly hospitalized patients: a double blind randomised trial comparing abrupt versus gradual withdrawal. Int J Med Sci, 12:294–296Google Scholar
  80. Tiberge M, Calvet U, Khayi N, Delahaye C, Arbus L (1988) Comparaison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. L'Encéphale 14:319–324Google Scholar
  81. Trifiletti RR, Snyder SH (1984) Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 26:458–469Google Scholar
  82. US Department of Health Education and Welfare (1977) Guidelines for the clinical evaluation of hypnotic drugs. US Government Printing Office, Washington DCGoogle Scholar
  83. Vogel G, Scharf M, Walsh J, Roth T (1989) Effects of chronically administered zolpidem on the sleep of healthy insomniacs. Sleep Res 18:80Google Scholar
  84. Wheatley D (1988) Zolpidem and placebo: a study in general practice in patients suffering from insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 305–316Google Scholar
  85. Wickstrom E, Barbo SE, Dreyfus JF, Jerke D, Kleiven R, Slattbrekk R, Stray Tonnesen JN (1983) A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners. Pharmacology 27 [suppl 2]:165–172Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Malcolm Lader
    • 1
  1. 1.Institute of PsychiatryLondonUK

Personalised recommendations